Albuvirtide (Aikening)_Dosage, benefits & legal status
Also known as Aikening, ABT, FB006M, FB-006M, 艾博卫泰
The second-generation fusion inhibitor that solved enfuvirtide's twice-a-day problem.
What is Albuvirtide (Aikening)?
Plain language first. The technical label stays, but it never stands alone.Overview
A weekly HIV infusion that hitches a ride on a protein already in your blood.
A 3-maleimidopropionic acid modified gp41 C34 analog that conjugates covalently to serum albumin Cys34, permitting once-weekly intravenous dosing; approved in China in 2018.
What it's used for
A prescription HIV treatment in China, given with other antiretroviral drugs in people whose previous regimen failed.
How does Albuvirtide (Aikening) work?
What it does in the body, and where.HIV gets into a cell by pulling the viral and cell membranes together. Its gp41 protein does the pulling: it folds in on itself, bringing two membranes into contact. Fusion inhibitors are decoy peptides that jam that fold. The old problem was that such peptides vanish from the blood in hours.
- 01It is built on C34, a known decoyC34 is a 34-residue stretch copied from the C-terminal heptad repeat of gp41, the region that normally folds back against the protein's own core. Supplied as a free peptide, it binds that core and stops the fold. Albuvirtide takes C34 as its template, with two residues not involved in target binding swapped to glutamate to improve solubility, stability and antiviral activity.
- 02The real invention is one chemical groupA single 3-maleimidopropionic acid group is attached to the peptide. Maleimide reacts fast and irreversibly with free thiols, and human serum albumin carries exactly one accessible free cysteine, Cys34. The reaction is roughly a thousandfold faster at that site than at other thiols, so the peptide attaches to albumin at a clean one-to-one ratio.
- 03Albumin is the delivery vehicleAlbumin circulates for weeks. By covalently hitching itself to it, the peptide inherits that lifetime. That is what turns a drug that would need dosing several times a day into one given once a week. The conjugation happens in the body after infusion, not in the vial.
- 04What that produced in practiceApproval in China in 2018, after phase 3 work including the TALENT study, which tested it with lopinavir and ritonavir in people whose first-line regimen had failed. It is the first approval of a second-generation, long-acting peptide HIV fusion inhibitor. It remains approved in China and, per a United States government drug database, certain other countries, which that database does not name.

What else is it used for?
Each use below carries its own evidence level. Approved means regulators have cleared it for that purpose. Investigational means it is in trials. Early research means it is being studied and is not established.
- HIV-1 treatment in combination regimens, the approved Chinese indicationClinical use
- Post-exposure prophylaxis, the subject of later observational researchEarly research
- Hepatitis C and coronavirus programs, listed by a peptide drug database with no results read herenone
The published record
Papers about Albuvirtide (Aikening) · this compound only
Searched: Albuvirtide, Aikening, FB006M.
Left out: ABT (three letters, also a common drug code prefix); C34 (the peptide this one was built from, a different molecule); gp41 (the viral protein it targets, with a very large literature of its own); enfuvirtide (the earlier fusion inhibitor, a different molecule with its own page); T-20 (that drug's code, which also matches time-point labels in unrelated papers); sifuvirtide (another fusion inhibitor built from the same template); TALENT (the phase 3 trial's name, which is also an ordinary word); maleimidopropionic acid (a chemical linker used on many unrelated molecules); 艾博卫泰 (the Chinese name, which this research database indexes very little of); 1417179-66-8 (the CAS number, which does not appear in titles or abstracts).
39 papers tagged human · 24 not reviews or lab · 5 clinical trial publications
How the compound was given: 3 applied to skin · 9 injected · 10 by mouth or rectal · 23 route not stated in the abstract
Read from each paper's indexing terms and abstract, by rule. A paper that mentions a cream studied a cream, not necessarily the product being sold.
9 registered trials · none with posted results
Furthest stage reached: Approved outside the US, China
Counted from Europe PMC indexing, not read by a person; a human tag can land on reviews, commentary or lab papers; clinical trial publications is the narrower count. A preprint and its journal version count once. 40 papers and 9 trials held here.

At a glance
Four things to know about Albuvirtide (Aikening)
Evidence
Clinical use
Category
Immune support
Common vial
Varies
Half-life
Not published
How much, and do you cycle it?
The range, and whether you take breaks.Once weekly (approved Chinese regimen), once weekly. Continuous weekly treatment Clinical use
HIV treatment is lifelong and continuous. There is no cycling, no break and no course length: the regimen runs for as long as it is working, and interruption risks resistance. This is how antiretroviral therapy is given everywhere, not a statement about this drug's own label, which was not read at source here.
Not publishedNo figure
No measured human half-life figure was read at source during this review, so none is printed here. The once-weekly dosing interval implies a long one, and the mechanism explains why: the peptide conjugates irreversibly to serum albumin, which itself circulates for weeks, so the drug's persistence is effectively albumin's persistence. That is a design argument rather than a measurement.
You can compare this against the whole library to see where it sits.
How is it given?
Dosing context and source notes.Given in hospital from a prepared product, so there is nothing to mix.
No milligram figure from the approved Chinese label was read at source during this review, so none is printed here. What is established across independent sources is the regimen shape: a once-weekly intravenous infusion, given as part of a combination antiretroviral regimen. The once-weekly interval is the entire point of the molecule's design. Any milligram figure circulating for this compound did not come from a label read here, and this is a hospital-administered prescription infusion rather than anything a person doses themselves.
How do you store it?
Before mixing, and after.Given in a hospital or trial clinic, so the pharmacy stores it.
Albuvirtide (Aikening) goes into a vein and is prepared by hospital, clinic or trial pharmacy staff, following the product label or the trial protocol. Some products like this are ready-made solutions and others are powders mixed just before use, often with hours rather than weeks of shelf life once prepared. It is not a medicine people store at home.
What are the side effects and cautions?
Known cautions and warnings for this compound.Who should avoid it
- Any use outside a prescription HIV regimen managed by a clinician, since this is a hospital-administered infusion for a chronic infection
- Use as a standalone treatment, because fusion inhibitors are given alongside other antiretrovirals
- Any assumption that it is available or approved in the United States or Europe, because it is not
Stop and get help
- Any allergic or infusion reaction, meaning rash, swelling of the face or lips, or trouble breathing
- Fever or signs of a new infection, which in HIV care need same-day assessment
- Nothing about an antiretroviral should be stopped without a clinician, because interruption drives resistance
Common effects
- Notably free of the injection site reactions that limited enfuvirtide, per reporting at the time of approval.
- Given once weekly rather than twice daily, which is the practical difference patients notice.
Where this page says nothing is established, that means nobody has studied it, not that a compound is safe.
Is Albuvirtide (Aikening) approved?
And where the numbers on this page come from.Not approved, but legal to obtain. Albuvirtide (Aikening) has no FDA approval, and it can be prescribed or prepared by a compounding pharmacy in the United States. It is approved in China, but not in the United States.
- Approval statusClinical use
- RouteInto a vein (intravenous infusion)
- Checked21 November 2026
- Approved outside the USChina.This does not change the United States position above.
- DoseNo dose has been established in people.
- Vial sizeFrom what vendors typically list; not a recommendation.
- SourcesUnited States National Institutes of Health HIV drug database, albuvirtideBiophysical Property and Broad Anti-HIV Activity of Albuvirtide, a 3-Maleimimidopropionic Acid-Modified Peptide Fusion Inhibitor, PLOS ONEDRAVP peptide drug database entry, albuvirtideHIV Treatment Bulletin, China approves albuvirtide: a once-weekly injectable entry inhibitorUS11680086, Lipopeptide for potently inhibiting HIV, derivative thereof, pharmaceutical composition thereof and use thereofReview repeating the N-terminal origin claim, The Role of Peptides in Combatting HIV Infection
What has happened recently
Approved in China, not in the United States or Europe. A United States government HIV drug database records marketing approval in China for the treatment of HIV and states that the drug is approved in China and in certain other countries, without naming them. The approval date is reported inconsistently across sources: a drug intelligence database gives 23 May 2018, the developer's own announcement is dated 6 June 2018, and the government database says June 2018. The regulator's own record was not read at source during this review, so no single date is asserted here. There is no FDA or EMA label for this product, which means no approved prescribing information exists in English to check dosing or safety against. A laboratory reagent catalog lists a trifluoroacetate salt of the peptide with stock shown; that is research material, a salt form is not a separate molecule, and such a listing establishes nothing about authenticity or suitability for a person.
You can compare this against the whole library, or read how to check a seller.
What else is like Albuvirtide (Aikening)?
Others in Immune support, side by side.If you're weighing Albuvirtide (Aikening), it's worth reading Evuzamitide (AT-01), Thymalin, and Vilon in the same class.
The second-generation fusion inhibitor that solved enfuvirtide's twice-a-day problem.
- Dose
- Once weekly (approved Chinese regimen)
- How often
- Once weekly
Forty-five residues designed to stick to the sugar scaffolding every kind of amyloid is built on.
- Dose
- A single tracer dose before imaging
- How often
- Once per scan
A thymus peptide taken in courses to refresh immune function and aging.
- Dose
- 5 up to 10 mg per day (start low, increase slowly)
- How often
- 10-day courses
A tiny bioregulator taken in courses for immunity and aging, with thin evidence.
- Dose
- Varies (course-based)
- How often
- Courses
Guides for this compound
- How to Reconstitute a Peptide
Mix peptide powder with bacteriostatic water, step by step.
- How to Read an Insulin Syringe
Read the units, convert to millilitres, and draw the exact dose.
- mcg vs mg: The Peptide Dosing Mistake to Avoid
Your vial says mg and your protocol says mcg. Here is the conversion and how to check it.
Sources
- United States National Institutes of Health HIV drug database, albuvirtide(2026)A United States government HIV drug database record, read for the identity, the names and the regulatory status. It gives the other names ABT, Aikening and FB006M, the drug class fusion inhibitor, CAS registry number 1417179-66-8, and the developing organization. It records that in June 2018 albuvirtide received marketing approval in China for the treatment of HIV, and that it is approved in China and in certain other countries. It describes the molecule as a peptide derived from the C-terminal heptad repeat sequence of HIV-1 gp41 and modified to contain a single 3-maleimimidopropionic acid group, which prevents HIV replication by binding gp41 and inhibiting formation of the six-helix bundle required for fusion of the viral and cellular membranes. It also names the TALENT study in its resistance section.
- Biophysical Property and Broad Anti-HIV Activity of Albuvirtide, a 3-Maleimimidopropionic Acid-Modified Peptide Fusion Inhibitor, PLOS ONE(2012)The originating biophysical paper, read for how the molecule was built, which is the part this card turns on. It states that albuvirtide is a 3-maleimimidopropionic acid modified peptide HIV fusion inhibitor that can irreversibly conjugate to serum albumin, that it was designed with the C34 sequence as a template, and that two other residues not involved in target binding were substituted by glutamic acid to improve solubility, stability and antiviral activity. It records that the engineered peptide links covalently to serum albumin at a one to one molecular ratio through an irreversible reaction between the maleimide and albumin's free thiol.
- DRAVP peptide drug database entry, albuvirtide(2026)A peptide drug database entry, read for the chemical identifiers that the government record does not carry. It gives the molecular formula C204H306N54O72, PubChem identifier 134694278, ChEMBL identifier CHEMBL4297257, UNII MG9PC54E43 and CAS 1417179-66-8, and describes albuvirtide as a 3-maleimimidopropionic acid modified peptide derived from the C-terminal heptad repeat sequence of HIV-1 gp41 that binds gp41 and blocks entry. It notes that the modification point is marked as a variable position in the stored sequence.
- HIV Treatment Bulletin, China approves albuvirtide: a once-weekly injectable entry inhibitor(2018)Independent HIV treatment reporting from the time of approval, read for the clinical framing and the enfuvirtide comparison. It records that on 6 June 2018 a press release from the developer announced approval of a new HIV drug in China given by once-weekly injection, that this was a rare case of an HIV treatment not approved first in the United States or Europe, and that from a safety perspective albuvirtide was not associated with the injection site reactions that limited the use of enfuvirtide. It also notes that little information about the completed phase 3 results supporting approval was publicly available at that time.
- US11680086, Lipopeptide for potently inhibiting HIV, derivative thereof, pharmaceutical composition thereof and use thereof(2023)A patent discussing the design lineage of this drug class, read to confirm what C34 is and where it sits. It states that most new-generation HIV membrane fusion inhibitors are based on the C-terminal heptad repeat polypeptide C34 of 34 amino acids as a template, that C34 corresponds to the amino acid sequence at positions 117 to 150 of gp41 and is considered the core C-terminal heptad repeat sequence, and it lists albuvirtide by name among the inhibitors obtained by optimization or modification of the C34 sequence.
- Review repeating the N-terminal origin claim, The Role of Peptides in Combatting HIV Infection(2024)A peer-reviewed review, cited here only to document the error this card corrects. It states that albuvirtide is a peptide modified with 3-maleimidopropionic acid and that it is derived from the N-terminal sequence of HIV-1 gp41. The same claim appears in at least one further review by overlapping authors. It contradicts the government drug database, the originating paper and the patent literature, all of which place the parent sequence in the C-terminal heptad repeat, and it is inconsistent with the C34 template the same literature describes.
Beyond these, 49 records are indexed for this compound. Browse the records
